Cardiovascular Business - January/February 2008 - (Page 21)

“spECt is really giving us hemodynamicsignificant information necessary for effective patient management.” — Gordon Depuey, MD, division of nuclear medicine, st. Luke’s-roosevelt Hospital SPECT’s great advantage is that, compared to exercise echo, it is “probably more accurate,” he says. “[SPECT’s] accuracy is similar to dobutamine echo, which can be technically inadequate due to hyper-expansion of the lungs, except SPECT has better inter-observer agreement and better precision,” says DePuey. Schoepf adds that the role of SPECT as the “premier modality” to assess myocardial perfusion will remain untouched by the introduction of CT coronary angiography (CTCA). The two cannot really be pitted against each other, he says. “[SPECT and CTCA] evaluate two very different aspects of coronary artery disease,” says Schoepf. “CTCA is specifically an anatomical and morphological test with the goal of detecting coronary arteries with stenosis. Myocardial perfusion imaging with SPECT is a completely different animal—its emphasis is on function. It has very little morphological information to it. One test looks at coronary artery obstruction or stensosis and the other looks at hemodynamic significance—both form a cornerstone method of imaging patients with suspected or confirmed CAD,” he says. “the most preferred camera type being considered, comprising more than two-thirds of the planned cameras.” Stephen Weiss, MD, operates a private cardiology practice, West Side Cardiology, in New York, N.Y. Weiss has been performing in-house SPECT studies for about three years to detect ischemic heart disease. For Weiss, the “most important aspect of SPECT ‘holding it’s own’ is that it has stood the test of time with an enormous wealth of clinical data to support its use as a diagnostic and prognostic tool for ischemia detection, assessment of myocardial infarction size, and risk stratification following a myocardial infarction. It is safe and reliable because it is reproducible and accurate, and it is relatively cost-effective given the alternatives,” he says. Weiss says the developments within SPECT imaging add to the wealth of information on how to use it, what its limits are and how to apply to the right patient. “It is not the right test for every patient and we know, thanks to the clinical and historical information backing it up, who should get it for what test,” he says. Proving its business value Aside from the diagnostic value that SPECT continues to prove, it also provides significant business value compared to other imaging studies. “This is a changing environment because reimbursement changes can happen at the stroke of a pen with CMS [Centers for Medicare & Medicaid Services], but currently, reimbursement for SPECT is pretty good,” says DePuey. DePuey says it is important to remember that “we have a huge installed base of myocardial perfusion SPECT cameras” in the outpatient setting and most of that has been in private cardiologists’ offices. “Considering the current economic climate, it is doubtful that these outpatient centers are going to throw away their nuclear cameras and invest in 64-slice CT or more expensive cardiac MR—perhaps if money were no object and reimbursement was excellent, then maybe we would be moving more rapidly over to CTCA, but it is not. The reality is that SPECT is well established and is here to stay for a long time.” According to a 2007 report from IMV Medical Information Division, while SPECT/CT is nipping at the heels of SPECT, comprising 10 percent of cameras installed in 2007, dual-head SPECT cameras are better detectors “For a number of years, things really plateaued and weren’t very interesting. Things have changed recently and it is a very exciting time for nuclear cardiology, and for SPECT,” says DePuey. New cameras are being developed that use new detector technology – instead of using sodium iodide, they use cadmium zinc telluride detectors which DePuey says have “much, much better energy resolution.” “This should provide us better image quality and presumably better diagnostic accuracy—it will be a huge advancement in terms of diagnostic accuracy, but also patient throughput, lab efficiency and cost efficiency,” he says. Also, DePuey says that new software is being developed to correct for loss of resolution when imaging patients via SPECT. An inherent problem with SPECT is that “the deeper you go, the more resolution you lose, and of course the heart is a deep structure.” New software methods are incorporating resolution recovery to correct for that loss with depth. These advancements do not mean that SPECT won’t be supplanted in the future by another modality, according to Weiss, but that currently, it is still an important tool. CardiovascularBusiness.com Cardiovascular Business 21 http://CardiovascularBusiness.com

Table of Contents Feed for the Digital Edition of Cardiovascular Business - January/February 2008

Cardiovascular Business - January/February 2008 Contents The Ticker: Quality Pays in Several Ways Cover Story: The Proof: Why Evidence-based Medicine Improves Cardiac Care Clinical Study Digest: Co-payments and Cath Labs Cardiac PET/CT Fills in Gaps Left by SPECT Tapping into IT to Improve the Office-Based Practice SPECT–Proving Its Value Cardiac Images in the EMR: Just a Click Away The Top 20 Ways to Market Your Cardiac CTA Practice The Big Picture: Medical Displays for Cardiac Images Statins Work But Pharmacoeconomic Caveats Abound Driving Data Protection: Opting for Storage On- or Offsite News & Views Calendar Reader’s Resource

Cardiovascular Business - January/February 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.